Molecular Profiling of Experimental Parkinson's Disease: Direct Analysis of Peptides and Proteins on Brain Tissue Sections by MALDI Mass Spectrometry

Journal of Proteome Research

Volumn 3, Issue 2, 2004, Pages 289-295

  Pierson, Johan ^a   Norris, Jeremy L ^b   Aerni, Hans Rudolf ^b   Svenningsson, Per ^c   Caprioli, Richard M ^b   Andrén, Per E ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cortex; L Dopa; MALDI; Parkinson's disease; Post translational modifications; Striatum

Indexed keywords

CALMODULIN; CYTOCHROME C; CYTOCHROME C OXIDASE; DOPAMINE; LEVODOPA; MOLECULAR MARKER;

ACETYLATION; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN MAPPING; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; MALE; MASS SPECTROMETER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PARKINSON DISEASE; PEPTIDE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROCESSING; RAT; REVIEW;

ADRENERGIC AGENTS; ANIMALS; ANTIPARKINSON AGENTS; BRAIN; CALMODULIN; CEREBRAL CORTEX; CORPUS STRIATUM; CYTOCHROMES C; DISEASE MODELS, ANIMAL; DOPAMINE; ELECTRON TRANSPORT COMPLEX IV; IONS; LEVODOPA; MALE; OXIDOPAMINE; PARKINSON DISEASE; PEPTIDES; PHENOTYPE; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

ANIMALIA;

EID: 3342996780     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr0499747     Document Type: Review

References (26)

1. Hornykiewicz, O. Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-Dopa). Br. Med. Bull. 1973, 29, 172-178.
2. Lotharius, J.; Brundin, P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 2002, 3, 932-942.
3. Kish, S. J.; Shannak, K.; Hornykiewicz, O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. New Engl. J. Med. 1988, 318, 876-880.
4. Nutt, J. G. Motor fluctuations and dyskinesia in Parkinson's disease. Parkinsonism Relat. Disord. 2001, 8, 101-108.
5. Ungerstedt, U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 1968, 5, 107-110.
6. Annett, L. E.; Rogers, D. C.; Hernandez, T. D.; Dunnett, S. B. Behavioural analysis of unilateral monoamine depletion in the marmoset. Brain 1992, 115(Pt 3), 825-856.
7. Ungerstedt, U. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiologica Scandinavica. Supplementum 1971, 367, 69-93.
8. Henry, B.; Crossman, A. R.; Brotchie, J. M. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 1998, 151, 334-342.
9. Stoeckli, M.; Chaurand, P.; Hallahan, D. E.; Caprioli, R. M. Imaging mass spectrometry: A new technology for the analysis of protein expression in mammalian tissues. Nat. Med. 2001, 7, 493-496.
10. Stoeckli, M.; Farmer, T. B.; Caprioli, R. M. Automated mass spectrometry imaging with a matrix-assisted laser desorption ionization time-of-flight instrument. J. Am. Soc. Mass Spectrom. 1999, 10, 67-71.
11. Paxinos, G.; Watson, C. The Rat Brain in Stereotaxic Coordinates, 4th ed.; Academic Press: San Diego, 1998.
12. Svenningsson, P.; Gunne, L.; Andren, P. E. L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset. Neuroscience 2000, 99, 457-468.
13. Chaurand, P.; Caprioli, R. M. Direct profiling and imaging of peptides and proteins from mammalian cells and tissue sections by mass spectrometry. Electrophoresis 2002, 23, 3125-3135.
14. Cohen, S. L.; Chait, B. T. Influence of matrix solution conditions on the MALDI-MS analysis of peptides and proteins. Anal. Chem. 1996, 68, 31-37.
15. Botting, C. H. The use of the slow crystallisation method to improve matrix-assisted laser desorption/ionisation time-of-flight signals for larger proteins. Rapid Commun. Mass Spectrom. 2000, 14, 2030-2033.
16. Figueroa, I. D.; Torres, O.; Russell, D. H. Effects of Water Content in the Sample Preparation for MALDI on the Mass Spectra. Anal. Chem. 1998, 70, 4527-4533.
17. Shimohama, S.; Sawada, H.; Kitamura, Y.; Taniguchi, T. Disease model: Parkinson's disease. Trends Mol. Med. 2003, 9, 360-365.
18. Canfield, D. R.; Spealman, R. D.; Kaufman, M. J.; Madras, B. K. Autoradiographic localization of cocaine binding sites by [3H]CFT ([3H]WIN 35, 428) in the monkey brain. Synapse 1990, 6, 189-195.
19. Soucy, J. P.; Mrini, A.; Lafaille, F.; Doucet, G.; Descarries, L. Comparative evaluation of [3H]WIN 35428 and [3H]GBR 12935 as markers of dopamine innervation density in brain. Synapse 1997, 25, 163-175.
20. Chaurand, P.; Schwartz, S. A.; Caprioli, R. M. Imaging mass spectrometry: a new tool to investigate the spatial organization of peptides and proteins in mammalian tissue sections. Curr. Opin. Chem. Biol. 2002, 6, 676-681.
21. Rubakhin, S. S.; Garden, R. W.; Fuller, R. R.; Sweedler, J. V. Measuring the peptides in individual organelles with mass spectrometry. Nat. Biotechnol. 2000, 18, 172-175.
22. Kortvely, E.; Gulya, K. Calmodulin, and various ways to regulate its activity. Life Sci. 2004, 74, 1065-1070.
23. 2+/calmodulin signaling system in the neural response to excitability. Involvement of neuronal and glial cells. Prog. Neurobiol. 1999, 58, 207-232.
24. Pretet, J. Step-by-step release of cytochrome c. Trends Cell Biol. 2002, 12, 251.
25. Ott, M.; Robertson, J. D.; Gogvadze, V.; Zhivotovsky, B.; Orrenius, S. Cytochrome c release from mitochondria proceeds by a two-step process. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 1259-1263.
26. Krishna, R. G.; Wold, F. Post-translational modification of proteins. Adv. Enzymol. Relat. Areas Mol. Biol. 1993, 67, 265-298.